An observational study in Asthma, sponsored by AstraZeneca. Completed at 24 sites in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-24.
Sponsored by AstraZeneca · Observational
We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for asthma in real life conditions. For this purpose we will include both patients that are treated with Symbicort® Turbuhaler® the "classical" maintenance only treatment approach as well as those treated with the SMART approach.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 400 is above the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 358 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
patients visiting pulmologist's office
Exclusion Criteria:
patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
to determine the efficacy of both possible treatment approaches with Symbicort® Turbuhaler®, measured by asthma control
Time frame: three times: 0, 3, 6 months after inclusion
to determine the number of maintenance and reliever inhalations of Symbicort® Turbuhaler®, as well as the concomitant usage of a separate reliever inhaler even in the case of SMART treatment approach
Time frame: three times: 0, 3, 6 months after inclusion
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca